Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)
Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)
The purpose of this study is to determine the efficacy, durability and long-term safety of reloxaliase in patients with enteric hyperoxaluria.
This is a phase 3, global, multi-center, randomized, double-blind, placebo-controlled study. This study is designed to determine the short- and long-term efficacy of reloxaliase in terms of reducing urinary oxalate excretion and clinical benefits compared to placebo.
Inclusion Criteria:
Exclusion Criteria:
Phoenix, Arizona 85016, United States
Glen Burnie, Maryland 21061, United States
New York, New York 10016, United States
Providence, Rhode Island 02916, United States
San Antonio, Texas 78229-3900, United States
Montreal, Quebec H2X 0A9, Canada
Rome, 00168, Italy
Mexico City, 11650, Mexico
Lausanne, CH 1011, Switzerland